WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--ROTATEQ® (rotavirus vaccine, live, oral, pentavalent), the pentavalent rotavirus vaccine from Merck & Co., Inc., that helps prevent rotavirus gastroenteritis in infants and children, has been awarded pre-qualification status by the World Health Organization (WHO). WHO pre-qualification allows for expanded access to ROTATEQ and provides a greater opportunity to help protect millions of babies from rotavirus gastroenteritis.
